Get the Stockscreener App
11.53
0.79%
0.09
After Hours:
11.30
-0.23
-1.99%
Biohaven Ltd stock is traded at $11.53, with a volume of 1.58M.
It is up +0.79% in the last 24 hours and up +45.03% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$11.44
Open:
$11.44
24h Volume:
1.58M
Relative Volume:
0.43
Market Cap:
$1.53B
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.5052
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
+20.73%
1M Performance:
+45.03%
6M Performance:
-26.04%
1Y Performance:
-71.29%
1-Day Range:
$11.13
$11.65
1-Week Range:
$9.70
$11.71
52-Week Range:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
11.53 | 1.52B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven (BHVN): Evaluating Valuation After New BHV-1510 Oncology Data at ESMO Immuno-Oncology Congress - simplywall.st
Bellevue Group AG Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Certain options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain warrants of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Biohaven Ltd. $BHVN Position Trimmed by Redmile Group LLC - MarketBeat
Armistice Capital LLC Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Biohaven jumps on early-stage data for antibody drug conjugate combo - Seeking Alpha
Why Biohaven (BHVN) Is Up 16.2% After New Trop2 ADC Combo Data At ESMO IO 2025 – And What's Next - simplywall.st
Biohaven stock jumps after promising cancer drug results By Investing.com - Investing.com Nigeria
Biohaven stock jumps after promising cancer drug results - Investing.com India
Biohaven presents data for BHV-1510 at ESMO - TipRanks
Biohaven reports promising results for cancer drug BHV-1510 - Investing.com
Biohaven reports promising results for cancer drug BHV-1510 By Investing.com - Investing.com South Africa
Biohaven shares cancer drug trial results at European oncology meeting - StreetInsider
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress - PR Newswire
Biohaven (NYSE:BHVN) Stock Price Down 5%What's Next? - MarketBeat
Norges Bank Makes New $12.74 Million Investment in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (NYSE:BHVN) Trading Up 8.8%Still a Buy? - MarketBeat
FY2025 EPS Estimates for Biohaven Increased by HC Wainwright - MarketBeat
Responsive Playbooks and the BHVN Inflection - news.stocktradersdaily.com
Biohaven Ltd. $BHVN Position Lowered by Panagora Asset Management Inc. - MarketBeat
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders - MSN
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% - Eastern Progress
Why Biohaven Ltd. stock could rally in 2025Jobs Report & Weekly Consistent Profit Watchlists - Newser
HC Wainwright Comments on Biohaven FY2029 Earnings - MarketBeat
Will Biohaven Ltd. Common Shares stock beat international competition2025 Institutional Moves & Weekly Setup with High ROI Potential - Newser
Will Biohaven Ltd. stock beat EPS estimatesJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Does Biohaven Ltd. stock trade at a discount to peersWeekly Trend Summary & Stock Portfolio Risk Management - Newser
Is Biohaven Ltd. Common Shares stock dividend growth reliableJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Biohaven (NYSE:BHVN) Shares Gap DownTime to Sell? - MarketBeat
Why Biohaven Ltd. Common Shares stock signals breakout potentialMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Biohaven to Neutral From Buy, Adjusts Price Target to $11 From $30 - marketscreener.com
Biohaven (BHVN) Receives Downgrade and Price Target Cut by HC Wa - GuruFocus
Biohaven downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
JPMorgan Chase & Co. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Capital Fund Management S.A. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Is Biohaven Ltd. Common Shares stock a defensive play amid uncertaintyPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Why Biohaven Ltd. stock appeals to dividend seekersJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - Newser
Why Is Biohaven Ltd. (BHVN) Stock Down Today? - Meyka
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
What downside risks could hit Biohaven Ltd. Common Shares stockWeekly Trade Recap & Pattern Based Trade Signal System - Newser
Biohaven (BHVN): Evaluating Valuation After UBS Downgrade and Shifting Analyst Sentiment - simplywall.st
Biohaven Ltd. $BHVN Stake Boosted by Geode Capital Management LLC - MarketBeat
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost - Yahoo Finance
Why Biohaven Ltd. Common Shares stock is a strong analyst pickCEO Change & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
The Bull Case For Biohaven (BHVN) Could Change Following Recent Analyst Downgrades - simplywall.st
RSI Check: Why retail investors favor Biohaven Ltd. stockM&A Rumor & Consistent Profit Trading Strategies - moha.gov.vn
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - AOL.com
Can Biohaven Ltd. stock outperform in 2025 bull market2025 Market WrapUp & Long Hold Capital Preservation Plans - moha.gov.vn
UBS Downgrades Biohaven (BHVN) - MSN
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):